Background The rate of contralateral risk-reducing mastectomy (CRRM) is increasing in the West with controversial evidence of improved survival in early breast cancer patients. Although uptake of CRRM in Asia appears low, the trends may rise, and there is currently an urgent need to provide evidence for informed decision-making in clinical practice. This study aims to determine the risk of contralateral breast cancer (CBC) and its associated factors in an Asian setting. Method A total of 2937 newly diagnosed patients with stage I and stage II breast cancer in University Malaya Medical Centre between Jan 1993 to Dec 2012 were included in the study. Multinomial logistic regression analysis allowing death to compete with CBC as a study outcome was used; patients with unilateral breast cancer who were alive were taken as reference. A stepwise backward regression analysis including age at diagnosis, ethnicity, family history of breast cancer, TNM stage, hormonal receptor status, HER2 status, chemotherapy, radiotherapy, and hormone therapy was conducted. Results Fifty women developed CBC, over a median follow-up of 6 years. The 5-and 10-year cumulative risk of contralateral breast cancer was 1.0% (95% CI 0.6-1.4%) and 2.8% (95% CI 2.0-3.6%), respectively. Young age at diagnosis of first cancer, positive family history, and stage I disease were independent predictors of CBC. Discussion The current study suggests that the risk of CBC is very low in a Southeast Asian setting. Any recommendations or practice of CRRM should be reviewed with caution and patients must be counseled appropriately.
Introduction
In the past few decades, survival following breast cancer has increased steadily in most parts of the world [1] attributed to early detection [2] and the advent of modern anticancer therapies [3, 4] . As breast cancer becomes a chronic condition, the survivors face many medical issues including long-term side effects of cancer therapy and increased risk of second primary malignancies [5] .
Contralateral breast cancer accounts for about 50% of all second primary cancer incidence in breast cancer survivors [6] . However, there is uncertainty about the lifetime risk of contralateral breast cancer (CBC) in a woman who is diagnosed with early stage breast cancer, with studies reporting risks ranging between 2 and 11% [6, 7] , with substantially higher risks in those with BRCA1/2 mutations.
In a retrospective review of over 2000 patients with family history of a BRCA1 or BRCA2 mutation, the cumulative risk of contralateral breast cancer 25 years after first breast cancer was 47.4% (95% CI 38.8-56.0%) [8] . While contralateral risk-reducing mastectomy (CRRM) may offer a clinical benefit in breast cancer patients with BRCA mutations and/or family history of breast cancer [9] , its value in patients without genetic predisposition is unclear.
Despite the lack of evidence on the survival gain conferred by CRRM [10] , rates seem to be increasing in the USA [11, 12] , as well as in Asian settings [13] . There is currently a scarcity of data on risk of contralateral breast cancer (CBC) in Asian women, where the incidence of breast cancer is lower than in Caucasians. We undertook this study to determine the risk of contralateral breast cancer in an unselected cohort of early staged breast cancer patients managed in a tertiary hospital in Southeast Asia. The findings of this study will enable evidence-based informed decision-making pertaining to CRRM in Asian breast cancer patients.
Methodology
This study was conducted using the University Malaya Breast Cancer Registry, which includes women who were newly diagnosed with primary breast cancer at University Malaya Medical Centre (UMMC), from January 1, 1993, to December 31, 2012 . The UMMC is a tertiary university hospital, situated in a relatively affluent part of Kuala Lumpur, catering to a predominantly urban population. Based on a report of the National Cancer Registry in 2006, UMMC managed approximately 10% of the newly diagnosed breast cancer patients in Malaysia. The UMMC Breast Cancer Registry had received approval of the institution's ethical review committee. Details of the registry had been described previously [14] .
Study population
In the current study, CBC was defined as tumor in the contralateral breast, diagnosed more than 6 months following the diagnosis of the first breast cancer.
Women who were diagnosed with a first primary breast cancer at stage III or stage IV were excluded. Among breast cancer patients with stage I or stage II disease at initial diagnosis, we further excluded 24 women who were diagnosed with a tumor in the contralateral breast within 6 months from their initial diagnosis. Following these exclusions, we had 2937 women in the present analysis.
Study variables
We included data on patient's age at diagnosis of first breast cancer, self-reported ethnicity (Chinese, Malay, Indian) and family history of breast cancer (presence of a first-or second-degree relative with breast cancer). Variables on tumor characteristics included tumor size (in cm), number of involved axillary lymph nodes, tumor grade (Scarff-Bloom-Richardson classification; grade 1, grade 2, grade 3), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. The estrogen receptor (ER) and progesterone receptor (PR) status were determined by immunohistochemistry and considered positive if [ 10 per cent of tumor cell nuclei were stained. HER2 was assessed through immunohistochemistry (IHC) and based on a staining intensity that was classified as 0 (negative), 1?, 2? or 3? according to the criteria set by DAKO. No available data regard to the high risk status in this subset group of patients in view of the unavailability of the routine BRCA testing in all the patients.
Follow-up
Patients were monitored through scheduled follow-up in the specialist breast cancer clinics in UMMC. Data on CBC were obtained from the clinical, radiological, and pathological records, and in some instances through active follow-up with patients. This is due to the need for the confirmation of the incidence of contralateral breast cancer during the follow-up period from the start of first primary to second primary cancer. Data on mortality were obtained from the hospitals' medical records. Vital status was additionally verified through direct linkage with National Registration Department, which holds the birth and death records of Malaysian nationals. Seventy-three patients were lost to follow-up.
Statistical analysis
The main study outcome was incidence of contralateral breast cancer. Kaplan-Meier analysis was used to estimate cumulative risk of CBC. Follow-up time was calculated as the interval between date of first primary breast cancer diagnosis and date of diagnosis with CBC, or date of last contact/death, whichever came first. Factors associated with incidence of CBC was assessed using multivariable analysis; A multinomial logistic regression analysis, which allows death (within 5 years) to compete with contralateral breast cancer as a study outcome was utilized, where patients with unilateral breast cancer who were alive at 5 years were taken as the reference group. A stepwise backward multinomial logistic regression analysis was conducted with age at diagnosis, ethnicity, family history of breast cancer, tumor size, number of positive axillary lymph nodes, ER status, PR status, HER2 status, chemotherapy, radiotherapy, and hormone therapy included in the initial step.
Two-sided p values and odds ratio (OR) for mortality, along with their 95% confidence intervals (CI) were included in the analysis. For all analyses, our threshold for statistical significance was 0.05. Data analyses were performed using SPSS for Windows version 22.0.
Results
In this cohort of 2937 patients presenting with TNM stage 1 and stage 2 disease at initial breast cancer diagnosis, 50 contralateral breast cancers, and 556 deaths were observed over a median follow-up of 6.0 years (interquartile range 3.4-9.4 years). The 5-, and 10-year cumulative risk of contralateral breast cancer was 1.0% (95% CI 0.6-1.4%) and 2.8% (95% CI 2.0-3.6%), respectively.
Median age at diagnosis of breast cancer in the overall cohort was 52 years. Women developing contralateral breast cancers were significantly younger at diagnosis (median age = 47) than their counterparts with unilateral breast cancer ( Table 1) . Incidence of contralateral breast cancer did not vary by ethnicity, nor was found to be affected by women reporting a family history of breast cancer. Patients with stage I breast cancer (median tumor size: 1.8 cm) were more likely to be associated with risk of contralateral breast cancer compared to women with stage II breast cancer (median tumor size: 2.5 cm). Neither hormone receptor status, HER2 status nor tumor grade was associated with contralateral breast cancer. Although chemotherapy administration was more likely to be associated with risk of contralateral breast cancer, this association was not statistically significant ( Table 2) . Receipt of radiotherapy and hormone therapy was not associated with risk of contralateral breast cancer.
In a stepwise backward multinomial regression analysis including all of the previously mentioned variables, smaller tumor size was found to be independently associated with risk of contralateral breast cancer (multivariable OR:0.76, 95% CI 0.61-0.96) (Table 3) . Ethnicity, tumor size, nodal status, PR status, grade, and chemotherapy were significantly and independently associated with mortality following breast cancer.
Discussion
Based on the current study, it appears that the 5-and 10-year cumulative risk of contralateral breast cancer is low (1.0 and 2.8%) for women with early breast cancer. The SEER database found that CBC was 4.2% with a median follow-up time of 4.5 years (0.25-23.6 years). The 5-, 10-, 15-, and 20-year incidence rates of CBC were higher at 3, 6.1, 9.1, and 12%, respectively [15] .
Multiple studies on CBC showed reduction in CBC rate due to usage of systemic adjuvant therapy [16, 17] . Nicholas et al. showed that the incidence of CBC declined in patients who had ER-positive tumors as compared to ER-negative tumors from 1990 to 2006 in a study using SEER database (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) [18] . A recent retrospective study of a cohort of 2070 Japanese breast cancer patients found that the incidence of contralateral breast cancer per 1000 person-years was 5.1 (95% CI 3.7-7.1) among patients without endocrine therapy (n = 1364) and 3.6 (95% CI 2.1-6.1) among those with endocrine therapy (n = 70) [19] . Our findings show a lower rate of contralateral breast cancer finding as findings as compared to other studies, and that systemic adjuvant therapy and ER status were not significantly associated with the incidence of CBC.
In our study, younger age, positive family history and stage 1 disease were associated with risk of contralateral breast cancer. A numbers of studies have revealed that younger age at diagnosis is associated with higher risk of contralateral breast cancer [20] [21] [22] [23] [24] [25] [26] [27] [28] . The earlier a woman develops an initial breast cancer in her lifetime, the greater the risk of developing a second primary breast cancer in her lifetime. Some studies have demonstrated that a family history of breast cancer is associated with an increased risk of contralateral breast cancer. The effect of a family history was particularly obvious among women with an affected first-degree relative [26] [27] [28] . A population-based casecontrol study in young women with breast cancer showed that those who have a family history of breast cancer [29] and who test negative for deleterious mutations in BRCA1 and BRCA2 were at a significantly greater risk of CBC than other breast cancer survivors. Women with a first-degree family history of bilateral disease have risks of CBC similar to mutation carriers [29] . Narod et al. demonstrated higher risk of contralateral breast cancer with unaffected mother, 8.4% (95% CI 8.1-8.7%), 12% (95% CI 11-13%) for a woman with a mother with unilateral breast cancer and was 13% (95% CI 9.5-17%) for women with a mother with bilateral breast cancer [29] . The current study also showed that stage 1 disease is associated with contralateral breast cancer. This is probably explained by a higher proportion of patients in this group who do not receive systemic treatment, e.g., chemotherapy as compared to stage 2 disease. It is also possible that women with Stage 1 breast cancer survive longer and hence there is a longer period for a CBC to develop. However, further prospective studies will be needed to confirm this finding. The rate of CRRM has been increasing in USA as shown in a study on 2965 patients with Stage 0-3 breast cancer at [30] . Meanwhile, in Asia, a study in Singapore showed that the CRRM rate increased from 0.46% in 2001 to 1.25% in 2010 [13] . A Markov model to simulate survival outcomes after CRRM and no CRRM among women with stage I or II breast cancer without a BRCA mutation showed that absolute 20-year survival benefit from CRRM was less than 1% among all ages, ER status, and stages [31, 32] . The addition of CRRM also increases healthcare utilization and cost [33] . Because of the rising number of women with unilateral breast cancer requesting for CRRM, the American Society of Breast Surgeons developed a consensus statement in 2016 that CRRM should be discouraged in average-risk women with unilateral breast cancer as there is no oncological benefit in carrying out the procedure [34] . Although uptake of CRRM in Asia has not been reported extensively and appears low, the trends may rise and evidence is needed to counsel patients on the benefits and harms of CRRM if patients request for CRRM. Given that there is a lower lifetime risk of breast cancer in Malaysia (5% average risk compared to 10-12% in the West) and based on this study, a lower risk of CBC was found compared to non-BRCA carriers seen in a systematic review [35] . There is an urgent need to document the risk of contralateral breast cancer in Asia. Due to the hospitalbased nature of this study, it remains possible that we may have underestimated the risk of CBC. While a vast majority of our patients adhered to follow-up for at least 5 years, there may be some women who sought treatment elsewhere. The underestimation is less likely to be a problem in assessment of the 5-year risk but cannot be ruled out in estimation of 10-year risk. Nevertheless, this data although from a single institution is the first to report the CBC rates in an Asian setting. Our study appears to suggest that risk of contralateral breast cancer is very low in multiethnic Southeast Asian patients. The uptake and impact of CRRM remain unknown in these setting [36] . Therefore, any clinical decision-making with regard to CRRM should be dealt with caution and discussed at length with patients. 
